Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)

Published:2014-09-22 Issue:6 Volume:29 Page:1082-1090
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Paul C.¹,Lacour J.-P.²,Tedremets L.³,Kreutzer K.⁴,Jazayeri S.⁵,Adams S.⁶,Guindon C.⁷,You R.⁸,Papavassilis C.⁹,

Affiliation:

1. Department of Dermatology; Paul Sabatier University; Toulouse France

2. Department of Dermatology; University Hospital of Nice; Nice France

3. Medicum Ltd; Tallinn Estonia

4. Städtische Kliniken Bielefeld; Bielefeld Germany

5. Alliance Dermatology and MOHS Center; Phoenix Arizona USA

6. University of Calgary; Calgary Alberta Canada

7. Novartis Pharmaceuticals Corporation; East Hanover New Jersey USA

8. Beijing Novartis Pharma Co. Ltd; Shanghai China

9. Novartis Pharma AG; Basel Switzerland

Funder

Novartis Pharmaceuticals

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.12751/fullpdf

Reference23 articles.

1. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings;Martin;J Invest Dermatol,2013

2. Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity;Zhang;Clin Immunol,2010

3. Interleukin-17 as a drug target in human disease;Ivanov;Trends Pharmacol Sci,2009

4. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis;Hueber;Sci Transl Med,2010

5. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study;Papp;Br J Dermatol,2013

Cited by 262 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

2. Efficacy and safety of secukinumab in psoriasis: five-year real life experience;Anais Brasileiros de Dermatologia;2024-07

3. Patient Experience with the SensoReady® Autoinjector Pen versus a Comparator Device: Results from a Canadian Patient Survey in Rheumatoid Arthritis and Crohn´s Disease;Patient Preference and Adherence;2024-06

4. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence;Autoimmunity Reviews;2024-04

5. Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials;Frontiers in Medicine;2024-03-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3